Journal ArticleDOI
Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients
David S. Boyer,David Faber,Sunil Gupta,Sunil S. Patel,Homayoun Tabandeh,Xiao-yan Li,Charlie C Liu,Jean Lou,Scott M. Whitcup +8 more
TLDR
Treatment with dexamethasone intravitreal implant led to statistically and clinically significant improvements in both vision and vascular leakage from diabetic macular edema in difficult-to-treat vitrectomized eyes and had an acceptable safety profile.Abstract:
Purpose:To evaluate the safety and efficacy of Ozurdex (dexamethasone intravitreal implant) 0.7 mg in the treatment of diabetic macular edema in vitrectomized eyes.Methods:This was a prospective, multicenter, open-label, 26-week study. Fifty-five patients with treatment-resistant diabetic macular edread more
Citations
More filters
Journal ArticleDOI
Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema.
David S. Boyer,Young Hee Yoon,Rubens Belfort,Francesco Bandello,Raj K. Maturi,Albert J. Augustin,Xiao-yan Li,Harry Cui,Yehia Hashad,Scott M. Whitcup +9 more
TL;DR: The DEX implant 0.7 mg and 0.35 mg met the primary efficacy endpoint for improvement in BCVA, and the safety profile was acceptable and consistent with previous reports.
Journal ArticleDOI
Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA).
Ursula Schmidt-Erfurth,José García-Arumí,Francesco Bandello,Karina Berg,Usha Chakravarthy,Bianca S. Gerendas,Jost B. Jonas,Michael Larsen,Ramin Tadayoni,Anat Loewenstein +9 more
TL;DR: As a consequence of recent rigorous clinical trials, laser photocoagulation is no longer recommended for the treatment of diabetic macular edema, and anti-vascular endothelial growth factor therapy has emerged as first-line therapy and Steroids have maintained a role in the management of chronically persistent DME.
Journal ArticleDOI
A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study.
Mark C Gillies,Lyndell L Lim,Anna Campain,Godfrey J. Quin,Wedad Salem,Ji Li,Stephanie Goodwin,Christine Aroney,Ian L. McAllister,Samantha Fraser-Bell +9 more
TL;DR: In this article, the authors reported the 12-month results of the first head-to-head comparison of a dexamethasone implant (Ozurdex; Allergan, Inc., Irvine, CA) versus bevacizumab (Avastin; Genentech, South San Francisco, CA).
Journal ArticleDOI
Dexamethasone Intravitreal Implant in Combination with Laser Photocoagulation for the Treatment of Diffuse Diabetic Macular Edema
David Callanan,Sunil Gupta,David S. Boyer,Thomas A. Ciulla,Michael A Singer,Baruch D. Kuppermann,C.-C. Liu,Xiao-yan Li,David A Hollander,Rhett M. Schiffman,Scott M. Whitcup +10 more
TL;DR: Significantly greater improvement in BCVA, as demonstrated by changes from baseline at various time points up to 9 months and across time based on the area under the curve analysis, occurred in patients with diffuse DME treated with DEX implant plus laser than in patients treated with laser alone.
Journal ArticleDOI
Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes.
Joan-En Chang-Lin,James A. Burke,Qing Peng,Ton Lin,Werhner C. Orilla,Corine Ghosn,Kai-Ming Zhang,Baruch D. Kuppermann,Michael R. Robinson,Scott M. Whitcup,Devin F. Welty +10 more
TL;DR: The vitreoretinal pharmacokinetic profiles were similar between nonvitrectomized and vit rectomized eyes, consistent with clinical findings of the DEX implant in patients who have undergone vitrectomy and should reduce concerns about the use of the dextromethasone implant in eyes that have undergone Vitrectomy.
References
More filters
Journal ArticleDOI
Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema
Michael J. Elman,Lloyd Paul Aiello,Roy W. Beck,Neil M. Bressler,Susan B. Bressler,Allison R. Edwards,Frederick L. Ferris,Scott M. Friedman,Adam R. Glassman,Kellee M. Miller,Ingrid U. Scott,Cynthia R. Stockdale,Jennifer K. Sun +12 more
TL;DR: Intravitreal ranibizumab with prompt or deferred laser is more effective through at least 1 year compared with prompt laser alone for the treatment of DME involving the central macula.
Journal ArticleDOI
Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection
TL;DR: Because triamcinolone pharmacokinetics were characterized only in elderly patients with macular edema, the results cannot be extrapolated to other patient populations.
Journal ArticleDOI
A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Focal/Grid Photocoagulation for Diabetic Macular Edema
TL;DR: Over a 2-year period, focal/grid photocoagulation is more effective and has fewer side effects than 1-mg or 4-mg doses of preservative-free intravitreal triamcinolone for most patients with DME who have characteristics similar to the cohort in this clinical trial.
Journal ArticleDOI
Diabetic macular edema: pathogenesis and treatment.
TL;DR: It seems that combined pharmacologic and surgical therapy may be the best approach for the management of macular edema in diabetic patients.
Journal ArticleDOI
Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema.
Baruch D. Kuppermann,Mark S. Blumenkranz,Julia A. Haller,George A. Williams,David V. Weinberg,Connie Chou,Scott M. Whitcup +6 more
TL;DR: In persistent macular edema, a single dexamethasone DDS treatment produced statistically significant BCVA improvements 90 days after treatment and was well tolerated for 180 days.